Home › Research › Costs and economics
The social value of lecanemab for patients with early Alzheimer's disease in Japan
Igarashi A, Azuma-Kasai M, Tani M, Utsumi T, Shibahara H, Inoue S, Rothwell S, Kamanaka G, Sakata Y, Hiyoshi H, Tomita K. Journal of Alzheimer's Disease, 2026-05-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).ObjectiveThis study aims to evaluate the social value of lecanemab in Japan.MethodsThe social value was evaluated using a cost-effectiveness model. The intervention was lecanemab added to the standard of care (SOC), and the comparator was SOC alone. The effect of lecanemab was determined based on the phase III trial and subsequent long-term follow-up observation studies. Health outcomes were quantified in life years and quality-adjusted life years (QALYs). Both patient and caregiver utilities were considered by summing the absolute values of utility for both the caregiver and patient. The base-case analysis was conducted from the public healthcare and long-term care payer's perspectives.ResultsLecanemab extended the time spent in early AD, thereby maintaining quality of life (QOL), reducing caregiver burden, and medical and long-term care resource usage. The incremental QALYs were 1.31 QALYs for MCI due to AD and 0.85 QALYs for mild AD-D, and the incremental cost-effectiveness ratios (ICERs) were JPY 8.5 million /QALY and JPY 7.9 million /QALY ($1 = JPY 150), respectively.ConclusionsThe value-based price or the ICER of lecanemab varied greatly depending on the perspectives and the methods of reflecting caregiver QOL. In AD, where the progression of the illness spans a long period and had a significant impact on families and society, narrowly defined value assessments were not sufficient, indicating the need to consider broader social value.
What this study adds
Evidence grade: Moderate
These are modelled estimates of value that varied greatly depending on the perspectives and methods used, not direct evidence of clinical benefit. Reported effect size: ICER JPY 8.5 million/QALY (MCI due to AD) and JPY 7.9 million/QALY (mild AD dementia); incremental QALYs 1.31 and 0.85.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Igarashi, A., Azuma-Kasai, M., Tani, M., Utsumi, T., Shibahara, H., Inoue, S., et al. (2026). The social value of lecanemab for patients with early Alzheimer's disease in Japan. Journal of Alzheimer's Disease. https://doi.org/10.1177/13872877261447312
Vancouver
Igarashi A, Azuma-Kasai M, Tani M, Utsumi T, Shibahara H, Inoue S, et al. The social value of lecanemab for patients with early Alzheimer's disease in Japan. Journal of Alzheimer's Disease. 2026. doi:10.1177/13872877261447312. PMID: 42108615.
BibTeX
@article{igarashi2026-42108615,
author = {Igarashi, A. and Azuma-Kasai, M. and Tani, M. and Utsumi, T. and Shibahara, H. and Inoue, S. and Rothwell, S. and Kamanaka, G. and Sakata, Y. and Hiyoshi, H. and Tomita, K.},
title = {{The social value of lecanemab for patients with early Alzheimer's disease in Japan}},
journal = {Journal of Alzheimer's Disease},
year = {2026},
doi = {10.1177/13872877261447312},
pmid = {42108615},
url = {https://doi.org/10.1177/13872877261447312}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- In AD, where the progression of the illness spans a long period and had a significant impact on families and society, narrowly defined value assessments were not sufficient, indicating the need to consider broader social value.
Why it matters
In this cost-effectiveness model, lecanemab added to standard of care extended time spent in early Alzheimer's disease and produced incremental cost-effectiveness ratios of JPY 8.5 million per QALY for mild cognitive impairment due to Alzheimer's disease and JPY 7.9 million per QALY for mild Alzheimer's disease dementia. These are modelled estimates of value that varied greatly depending on the perspectives and methods used, not direct evidence of clinical benefit.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Effect sizeICER JPY 8.5 million/QALY (MCI due to AD) and JPY 7.9 million/QALY (mild AD dementia); incremental QALYs 1.31 and 0.85
- Evidence strengthModerate
Limitations
Cost data for AD treatment and long-term care may not reflect the actual situation in Japan because linked data are limited; patient utilities came from Japanese studies but caregiver utilities from international literature, and no utilities exist for Japanese amyloid-confirmed MCI; efficacy after lecanemab discontinuation was assumed to persist based on trial hazard ratios, with no trial data on post-discontinuation effect.
How this study scored 37/100
Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 36 of the 98 points we could judge it on, which is 37 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Kiyoyuki Tomita: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Tokyo: institution h-index 1,463 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42108615) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 36 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 98 points we could judge it on is 37 out of 100. |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.